[{"id":"7d7a1304-f3ad-4177-9429-c404e09df0b7","acronym":"","url":"https://clinicaltrials.gov/study/NCT06703593","created_at":"2025-02-26T11:48:22.442Z","updated_at":"2025-02-26T11:48:22.442Z","phase":"Phase 2","brief_title":"Prevention of Doxorubicin-induced Cardiotoxicity in Breast Cancer Patients","source_id_and_acronym":"NCT06703593","lead_sponsor":"British University In Egypt","biomarkers":" NPPB","pipe":"","alterations":" ","tags":["NPPB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 09/01/2023","start_date":" 09/01/2023","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2024-11-25"},{"id":"ace14595-99e8-420e-9166-795c4d92e444","acronym":"","url":"https://clinicaltrials.gov/study/NCT04896242","created_at":"2024-04-04T16:37:45.774Z","updated_at":"2024-07-02T16:35:11.391Z","phase":"","brief_title":"Multimodal Assesment of Acute Cardiac Toxicity Induced by Thoracic Radiotherapy in Cancer Patients","source_id_and_acronym":"NCT04896242","lead_sponsor":"Pontificia Universidad Catolica de Chile","biomarkers":" NPPB","pipe":"","alterations":" ","tags":["NPPB"],"overall_status":"Completed","enrollment":" Enrollment 47","initiation":"Initiation: 01/09/2020","start_date":" 01/09/2020","primary_txt":" Primary completion: 10/31/2022","primary_completion_date":" 10/31/2022","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2024-04-04"},{"id":"13d940c3-64f2-4c13-a92c-5be14974fb4b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03499808","created_at":"2021-01-18T17:13:44.637Z","updated_at":"2024-07-02T16:35:24.603Z","phase":"Phase 2","brief_title":"S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis","source_id_and_acronym":"NCT03499808","lead_sponsor":"SWOG Cancer Research Network","biomarkers":" NPPB","pipe":" | ","alterations":" Chr t(11;14) • Chr t(4;14) • Chr t(14;16)","tags":["NPPB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr t(11;14) • Chr t(4;14) • Chr t(14;16)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Sarclisa (isatuximab-irfc)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 43","initiation":"Initiation: 06/06/2018","start_date":" 06/06/2018","primary_txt":" Primary completion: 12/31/2023","primary_completion_date":" 12/31/2023","study_txt":" Completion: 07/31/2025","study_completion_date":" 07/31/2025","last_update_posted":"2024-01-04"},{"id":"08e2c5ac-1575-4dac-b4a3-278c8836bbba","acronym":"MICA","url":"https://clinicaltrials.gov/study/NCT02641145","created_at":"2021-01-18T12:50:50.883Z","updated_at":"2024-07-02T16:35:27.183Z","phase":"","brief_title":"Molecular Imaging of Primary Amyloid Cardiomyopathy","source_id_and_acronym":"NCT02641145 - MICA","lead_sponsor":"Brigham and Women's Hospital","biomarkers":" NPPB","pipe":"","alterations":" ","tags":["NPPB"],"overall_status":"Recruiting","enrollment":" Enrollment 171","initiation":"Initiation: 04/01/2016","start_date":" 04/01/2016","primary_txt":" Primary completion: 01/08/2025","primary_completion_date":" 01/08/2025","study_txt":" Completion: 01/08/2025","study_completion_date":" 01/08/2025","last_update_posted":"2023-12-04"},{"id":"f217b7d9-3e47-4a87-b909-a8c4c9782009","acronym":"DaunoDouble","url":"https://clinicaltrials.gov/study/NCT02140242","created_at":"2021-07-17T10:53:01.305Z","updated_at":"2024-07-02T16:35:36.908Z","phase":"Phase 3","brief_title":"Comparison Between Two Dose Levels of Daunorubicin and Between One vs. Two Induction Cycles for Adult Patients With AML","source_id_and_acronym":"NCT02140242 - DaunoDouble","lead_sponsor":"Technische Universität Dresden","biomarkers":" NPPB","pipe":"","alterations":" ","tags":["NPPB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e daunorubicin"],"overall_status":"Completed","enrollment":" Enrollment 721","initiation":"Initiation: 04/16/2014","start_date":" 04/16/2014","primary_txt":" Primary completion: 04/25/2022","primary_completion_date":" 04/25/2022","study_txt":" Completion: 04/25/2022","study_completion_date":" 04/25/2022","last_update_posted":"2023-09-15"},{"id":"29cbbf17-d2dd-40bd-a5c0-ccbd3082ff71","acronym":"CIBERbBECHO","url":"https://clinicaltrials.gov/study/NCT05769868","created_at":"2023-03-15T14:02:27.364Z","updated_at":"2024-07-02T16:35:49.243Z","phase":"Phase 3","brief_title":"Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments","source_id_and_acronym":"NCT05769868 - CIBERbBECHO","lead_sponsor":"Consorcio Centro de Investigación Biomédica en Red (CIBER)","biomarkers":" HER-2 • IL6 • MMP1 • NPPB • ST2","pipe":" | ","alterations":" EGFR positive","tags":["HER-2 • IL6 • MMP1 • NPPB • ST2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR positive"],"overall_status":"Recruiting","enrollment":" Enrollment 1000","initiation":"Initiation: 04/18/2023","start_date":" 04/18/2023","primary_txt":" Primary completion: 03/01/2027","primary_completion_date":" 03/01/2027","study_txt":" Completion: 09/01/2027","study_completion_date":" 09/01/2027","last_update_posted":"2023-05-01"},{"id":"8032317f-a8cf-49ab-b83f-b1a34edcf53f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05703126","created_at":"2023-01-27T15:00:05.185Z","updated_at":"2024-07-02T16:35:56.835Z","phase":"","brief_title":"Clinical and Diagnostic Significance of Endothelial Dysfunction and Myocardial Contractility in Patients With AML","source_id_and_acronym":"NCT05703126","lead_sponsor":"Samara State Medical University","biomarkers":" NPPB","pipe":"","alterations":" ","tags":["NPPB"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 12/01/2022","start_date":" 12/01/2022","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 08/03/2025","study_completion_date":" 08/03/2025","last_update_posted":"2023-01-27"},{"id":"06b88785-af6e-4b4b-82bf-5c542b623c0a","acronym":"","url":"https://clinicaltrials.gov/study/NCT02942615","created_at":"2021-07-17T10:53:23.931Z","updated_at":"2024-07-02T16:35:58.387Z","phase":"Phase 3","brief_title":"The Safety Management of Cardiac Toxicity in Breast Cancer Patients Under Multidiscipline Therapy.","source_id_and_acronym":"NCT02942615","lead_sponsor":"Ruijin Hospital","biomarkers":" NPPB","pipe":"","alterations":" ","tags":["NPPB"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 220","initiation":"Initiation: 06/27/2017","start_date":" 06/27/2017","primary_txt":" Primary completion: 10/08/2020","primary_completion_date":" 10/08/2020","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2022-12-29"},{"id":"1b6169ed-090d-4376-8bcb-7b155928b4b2","acronym":"HERAN2","url":"https://clinicaltrials.gov/study/NCT05548504","created_at":"2022-09-21T18:56:19.645Z","updated_at":"2024-07-02T16:36:03.636Z","phase":"Phase 2","brief_title":"Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC","source_id_and_acronym":"NCT05548504 - HERAN2","lead_sponsor":"Odense University Hospital","biomarkers":" NPPB","pipe":"","alterations":" ","tags":["NPPB"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 182","initiation":"Initiation: 10/01/2022","start_date":" 10/01/2022","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2029","study_completion_date":" 09/30/2029","last_update_posted":"2022-09-21"},{"id":"63e493d9-db2d-479b-a717-64bf3dba44d7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05411250","created_at":"2022-06-09T13:55:23.460Z","updated_at":"2024-07-02T16:36:09.156Z","phase":"","brief_title":"Early Diagnosis of Therapy-associated Cardiotoxicity Basing on PET/CT in Lymphoma","source_id_and_acronym":"NCT05411250","lead_sponsor":"Beijing Cancer Hospital","biomarkers":" NPPB","pipe":"","alterations":" ","tags":["NPPB"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 05/31/2023","primary_completion_date":" 05/31/2023","study_txt":" Completion: 07/31/2023","study_completion_date":" 07/31/2023","last_update_posted":"2022-06-09"},{"id":"f639df2f-b80b-4b0e-9bef-2bba3806e588","acronym":"","url":"https://clinicaltrials.gov/study/NCT02496260","created_at":"2021-01-18T12:02:16.669Z","updated_at":"2024-07-02T16:36:16.063Z","phase":"","brief_title":"Biomarkers and Cardiac MRI as Early Indicators of Cardiac Exposure Following Breast Radiotherapy","source_id_and_acronym":"NCT02496260","lead_sponsor":"Henry Ford Health System","biomarkers":" GDF15 • LGALS3 • CRP • MPO • NPPB","pipe":"","alterations":" ","tags":["GDF15 • LGALS3 • CRP • MPO • NPPB"],"overall_status":"Completed","enrollment":" Enrollment 25","initiation":"Initiation: 07/01/2015","start_date":" 07/01/2015","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 12/01/2018","study_completion_date":" 12/01/2018","last_update_posted":"2022-03-03"},{"id":"8f79b996-4fc6-4b46-b72b-7d9f18fdd3df","acronym":"","url":"https://clinicaltrials.gov/study/NCT05252065","created_at":"2022-02-23T19:55:00.860Z","updated_at":"2024-07-02T16:36:16.749Z","phase":"","brief_title":"Cardiac Substructure Radiation Dose and Early Clinical Monitoring of Stage N2-3 Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05252065","lead_sponsor":"Guizhou Medical University","biomarkers":" NPPB","pipe":"","alterations":" ","tags":["NPPB"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 02/28/2022","start_date":" 02/28/2022","primary_txt":" Primary completion: 12/30/2022","primary_completion_date":" 12/30/2022","study_txt":" Completion: 12/30/2022","study_completion_date":" 12/30/2022","last_update_posted":"2022-02-23"},{"id":"5c99b13b-4af2-4f4b-800a-eeb248e86803","acronym":"","url":"https://clinicaltrials.gov/study/NCT03892031","created_at":"2021-07-17T10:54:21.319Z","updated_at":"2024-07-02T16:36:16.998Z","phase":"","brief_title":"Circulatory Function in Laparoscopic Radical Cystectomy for Bladder Cancer","source_id_and_acronym":"NCT03892031","lead_sponsor":"RenJi Hospital","biomarkers":" NPPB","pipe":"","alterations":" ","tags":["NPPB"],"overall_status":"Completed","enrollment":" Enrollment 186","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 12/31/2019","primary_completion_date":" 12/31/2019","study_txt":" Completion: 12/31/2019","study_completion_date":" 12/31/2019","last_update_posted":"2022-02-17"},{"id":"3058e76e-fc9c-43b1-9345-f130b2b640d0","acronym":"","url":"https://clinicaltrials.gov/study/NCT03271047","created_at":"2021-01-18T16:09:18.628Z","updated_at":"2024-07-02T16:36:18.889Z","phase":"Phase 1b/2","brief_title":"Study of Binimetinib + Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Microsatellite-stable (MSS) Metastatic Colorectal Cancer With RAS Mutation","source_id_and_acronym":"NCT03271047","lead_sponsor":"Pfizer","biomarkers":" CEACAM5 • NPPB","pipe":" | ","alterations":" RAS mutation","tags":["CEACAM5 • NPPB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • Mektovi (binimetinib) • Braftovi (encorafenib)"],"overall_status":"Completed","enrollment":" Enrollment 75","initiation":"Initiation: 10/18/2017","start_date":" 10/18/2017","primary_txt":" Primary completion: 10/13/2020","primary_completion_date":" 10/13/2020","study_txt":" Completion: 02/25/2021","study_completion_date":" 02/25/2021","last_update_posted":"2022-01-04"},{"id":"814f978e-c28f-4c9d-8d9e-3e3bb33a09fe","acronym":"","url":"https://clinicaltrials.gov/study/NCT03908528","created_at":"2021-01-18T19:14:23.555Z","updated_at":"2024-07-02T16:36:23.198Z","phase":"","brief_title":"Alpha-Lipoic Acid in Breast Cancer Patients","source_id_and_acronym":"NCT03908528","lead_sponsor":"Damanhour University","biomarkers":" TNFA • NPPB","pipe":"","alterations":" ","tags":["TNFA • NPPB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • doxorubicin hydrochloride • cyclophosphamide"],"overall_status":"Completed","enrollment":" Enrollment 64","initiation":"Initiation: 03/01/2019","start_date":" 03/01/2019","primary_txt":" Primary completion: 10/30/2020","primary_completion_date":" 10/30/2020","study_txt":" Completion: 10/30/2020","study_completion_date":" 10/30/2020","last_update_posted":"2021-10-11"},{"id":"4475e9e6-54f7-448c-be00-7d33acb6ed32","acronym":"","url":"https://clinicaltrials.gov/study/NCT05040867","created_at":"2021-09-10T16:57:27.235Z","updated_at":"2024-07-02T16:36:24.618Z","phase":"","brief_title":"Exercise Prescription Guided by Heart Rate Variability in Breast Cancer Patients","source_id_and_acronym":"NCT05040867","lead_sponsor":"GO fit Lab- Ingesport","biomarkers":" IL6 • TNFA • IL10 • IL1B • CRP • NPPB","pipe":"","alterations":" ","tags":["IL6 • TNFA • IL10 • IL1B • CRP • NPPB"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 09/13/2021","start_date":" 09/13/2021","primary_txt":" Primary completion: 07/30/2022","primary_completion_date":" 07/30/2022","study_txt":" Completion: 09/20/2022","study_completion_date":" 09/20/2022","last_update_posted":"2021-09-10"},{"id":"1b36a1b4-ace5-4b0b-b4e6-9d2c998a777b","acronym":"ACCOLADE","url":"https://clinicaltrials.gov/study/NCT03645317","created_at":"2021-01-18T17:53:42.881Z","updated_at":"2024-07-02T16:36:27.164Z","phase":"","brief_title":"Avoiding Cardiac Toxicity in Lung Cancer Patients Treated With Curative-intent Radiotherapy","source_id_and_acronym":"NCT03645317 - ACCOLADE","lead_sponsor":"Prof Corinne Faivre-Finn","biomarkers":" CRP • NPPB","pipe":"","alterations":" ","tags":["CRP • NPPB"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 06/12/2019","start_date":" 06/12/2019","primary_txt":" Primary completion: 04/01/2022","primary_completion_date":" 04/01/2022","study_txt":" Completion: 07/01/2022","study_completion_date":" 07/01/2022","last_update_posted":"2021-08-02"},{"id":"5cb76cf5-0b24-4805-a18c-85f0ac0771c9","acronym":"INVEST","url":"https://clinicaltrials.gov/study/NCT03661801","created_at":"2021-01-18T17:58:03.910Z","updated_at":"2024-07-02T16:36:39.035Z","phase":"","brief_title":"Novel Pleural Fluid, Biopsy and Serum Biomarkers for the Investigation of Pleural Effusions","source_id_and_acronym":"NCT03661801 - INVEST","lead_sponsor":"University of Oxford","biomarkers":" MSLN • SPP1 • NPPB","pipe":"","alterations":" ","tags":["MSLN • SPP1 • NPPB"],"overall_status":"Completed","enrollment":" Enrollment 313","initiation":"Initiation: 10/26/2017","start_date":" 10/26/2017","primary_txt":" Primary completion: 12/31/2019","primary_completion_date":" 12/31/2019","study_txt":" Completion: 12/31/2019","study_completion_date":" 12/31/2019","last_update_posted":"2020-11-05"},{"id":"aeef7a6b-9bd7-465b-931b-13c38b95610e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04618094","created_at":"2021-01-19T20:33:56.313Z","updated_at":"2024-07-02T16:36:39.039Z","phase":"","brief_title":"Prehabilitation in Patients Suffering From Gynecological Cancers","source_id_and_acronym":"NCT04618094","lead_sponsor":"Medical University of Vienna","biomarkers":" IL6 • TNFA • CRP • NPPB","pipe":"","alterations":" ","tags":["IL6 • TNFA • CRP • NPPB"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 01/01/2021","start_date":" 01/01/2021","primary_txt":" Primary completion: 01/01/2022","primary_completion_date":" 01/01/2022","study_txt":" Completion: 01/01/2023","study_completion_date":" 01/01/2023","last_update_posted":"2020-11-05"},{"id":"2b0c47aa-7eb1-482c-8209-5d58feacf77b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02475057","created_at":"2021-01-18T11:54:59.787Z","updated_at":"2024-07-02T16:36:58.944Z","phase":"Phase 4","brief_title":"Endothelial Function in Prostate Cancer Patients on Degarelix vs. Luteinizing Hormone-Releasing Hormone Agonists","source_id_and_acronym":"NCT02475057","lead_sponsor":"Rabin Medical Center","biomarkers":" CRP • NPPB","pipe":"","alterations":" ","tags":["CRP • NPPB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Firmagon (degarelix)"],"overall_status":"Completed","enrollment":" Enrollment 80","initiation":"Initiation: 08/01/2015","start_date":" 08/01/2015","primary_txt":" Primary completion: 07/01/2018","primary_completion_date":" 07/01/2018","study_txt":" Completion: 06/01/2019","study_completion_date":" 06/01/2019","last_update_posted":"2019-06-12"},{"id":"c945bd91-71e5-4643-b2c7-9d795764c5c2","acronym":"","url":"https://clinicaltrials.gov/study/NCT00895414","created_at":"2021-05-19T21:52:37.845Z","updated_at":"2024-07-02T16:36:59.811Z","phase":"","brief_title":"Enalapril Maleate and Doxorubicin Hydrochloride in Treating Women With Breast Cancer","source_id_and_acronym":"NCT00895414","lead_sponsor":"Masonic Cancer Center, University of Minnesota","biomarkers":" NPPB","pipe":"","alterations":" ","tags":["NPPB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e doxorubicin hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 19","initiation":"Initiation: 04/01/2009","start_date":" 04/01/2009","primary_txt":" Primary completion: 04/01/2014","primary_completion_date":" 04/01/2014","study_txt":" Completion: 10/01/2015","study_completion_date":" 10/01/2015","last_update_posted":"2019-05-08"},{"id":"3b4a043d-0cd9-42d5-abbc-edbf7517ed3e","acronym":"","url":"https://clinicaltrials.gov/study/NCT02815007","created_at":"2021-07-17T10:53:19.799Z","updated_at":"2024-07-02T16:37:31.015Z","phase":"Phase 2","brief_title":"Chidamide With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT02815007","lead_sponsor":"Yuankai Shi","biomarkers":" NPPB","pipe":" | ","alterations":" EGFR mutation","tags":["NPPB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Epidaza (chidamide)"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 06/01/2016","start_date":" 06/01/2016","primary_txt":" Primary completion: 03/01/2018","primary_completion_date":" 03/01/2018","study_txt":" Completion: 06/01/2018","study_completion_date":" 06/01/2018","last_update_posted":"2016-06-28"}]